UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

Scientific reports, 2023-06, Vol.13 (1), p.10591-10591, Article 10591

2023

Volltextzugriff (PDF)

Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use

Reviews in cardiovascular medicine, 2022-04, Vol.23 (4), p.139

2022

Volltextzugriff (PDF)

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

Journal of the American College of Cardiology, 2021-11, Vol.78 (21), p.2042-2056

2021

Volltextzugriff (PDF)

Reply

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.e197-e198

2022

Volltextzugriff (PDF)

Reply: Beta-Blocker Withdrawal and Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.e197-e198

2022

Volltextzugriff (PDF)

Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA‐VO2): a randomized clinical trial

European journal of heart failure, 2022-10, Vol.24 (10), p.1816-1826

2022

Volltextzugriff (PDF)

Chronotropic Incompetence Predicts Distance Walked in Six-Minute Walk Test in Heart Failure With Preserved Ejection Fraction

Journal of cardiac failure, 2020-11, Vol.26 (11), p.1024-1025

2020

Volltextzugriff (PDF)

Índice cronotrópico y eventos adversos a largo plazo en insuficiencia cardiaca con fracción de eyección conservada

Revista española de cardiologia, 2023-07, Vol.76 (7), p.511-518

2023

Volltextzugriff (PDF)

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA‐MODA study

European journal of heart failure, 2023-08, Vol.25 (8), p.1352-1360

2023

Volltextzugriff (PDF)

Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

Journal of cardiac failure, 2023-05, Vol.29 (5), p.849-854

2023

Volltextzugriff (PDF)

La reducción temprana del filtrado glomerular se asocia con aumento de la hemoglobina tras el inicio de dapagliflozina en la insuficiencia cardiaca con fracción de eyección reducida

Revista española de cardiologia, 2023-10, Vol.76 (10), p.783-792

2023

Volltextzugriff (PDF)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)

Clinical cardiology (Mahwah, N.J.), 2020-05, Vol.43 (5), p.423-429

2020

Volltextzugriff (PDF)

β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction

JAMA cardiology, 2024-04, Vol.9 (4), p.392

2024

Volltextzugriff (PDF)

Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

JACC. Heart failure, 2023-11, Vol.11 (11), p.1611-1622

2023

Volltextzugriff (PDF)

Short-Term Changes in Peak VO 2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

JACC. Heart failure, 2023-11, Vol.11 (11), p.1611

2023

Volltextzugriff (PDF)

Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

Revista española de cardiología (English ed.), 2023-10, Vol.76 (10), p.783-792

2023

Volltextzugriff (PDF)

Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

Revista española de cardiología (English ed.), 2023-07, Vol.76 (7), p.511-518

2023

Volltextzugriff (PDF)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

Frontiers in cardiovascular medicine, 2023-08, Vol.10, p.1242108-1242108

2023

Volltextzugriff (PDF)

Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)

Journal of cardiovascular pharmacology, 2021-11, Vol.78 (5), p.e662-e668

2021

Volltextzugriff (PDF)

Aneurismas coronarios gigantes en lactantes con enfermedad de Kawasaki

Anales de pediatría (Barcelona, Spain : 2003), 2017-08, Vol.87 (2), p.65-72

2017

Volltextzugriff (PDF)

Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice

Journal of comparative effectiveness research, 2019-07, Vol.8 (9), p.685-697

2019

Volltextzugriff (PDF)

Giant coronary aneurysms in infants with Kawasaki disease

Anales de pediatría (Barcelona, Spain : 2003), 2017-08, Vol.87 (2), p.65-72

2017

Volltextzugriff (PDF)

Giant coronary aneurysms in infants with Kawasaki disease

Anales de Pediatría, 2017-08, Vol.87 (2), p.65-72

2017

Volltextzugriff (PDF)

494/12. LOS ANTICOAGULANTES ORALES PUEDEN REDUCIR EL RIESGO DE DETERIORO DE LA FUNCIÓN RENAL EN PACIENTES CON FIBRILACIÓN AURICULAR Y ENFERMEDAD RENAL CRÓNICA GRAVE. VIDA REAL

REC: CardioClinics, 2023-02, Vol.58, p.S4

2023

Volltextzugriff (PDF)

494/13. ANTICOAGULACIÓN ORAL EN MAYORES DE 80 AÑOS CON FIBRILACIÓN AURICULAR Y ENFERMEDAD RENAL CRÓNICA GRAVE

REC: CardioClinics, 2023-02, Vol.58, p.S5

2023

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(20)
Humans
(18)
Female
(14)
Male
(14)
Cardiac & Cardiovascular Systems
(13)
Cardiovascular System & Cardiology
(13)
Heart Failure
(8)
Mutation
(8)
Child
(7)
Dapagliflozin
(7)
Heart Failure - Drug Therapy
(7)
Aged
(6)
Heart Failure With Reduced Ejection Fraction
(6)
Middle Aged
(6)
Adolescent
(5)
Aged, 80 And Over
(5)
Child, Preschool
(5)
Maximal Functional Capacity
(5)
Stroke Volume
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

Reply

Reply: Beta-Blocker Withdrawal and Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction

Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA‐VO2): a randomized clinical trial

Chronotropic Incompetence Predicts Distance Walked in Six-Minute Walk Test in Heart Failure With Preserved Ejection Fraction

Índice cronotrópico y eventos adversos a largo plazo en insuficiencia cardiaca con fracción de eyección conservada

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA‐MODA study

Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

La reducción temprana del filtrado glomerular se asocia con aumento de la hemoglobina tras el inicio de dapagliflozina en la insuficiencia cardiaca con fracción de eyección reducida

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)

β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction

Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

Short-Term Changes in Peak VO 2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)

Aneurismas coronarios gigantes en lactantes con enfermedad de Kawasaki

Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice

Giant coronary aneurysms in infants with Kawasaki disease

Giant coronary aneurysms in infants with Kawasaki disease

494/12. LOS ANTICOAGULANTES ORALES PUEDEN REDUCIR EL RIESGO DE DETERIORO DE LA FUNCIÓN RENAL EN PACIENTES CON FIBRILACIÓN AURICULAR Y ENFERMEDAD RENAL CRÓNICA GRAVE. VIDA REAL

494/13. ANTICOAGULACIÓN ORAL EN MAYORES DE 80 AÑOS CON FIBRILACIÓN AURICULAR Y ENFERMEDAD RENAL CRÓNICA GRAVE

Suchergebnisse filtern